Rockefeller Capital Management
AVDL

Rockefeller Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Rockefeller Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,816
Closed -$39.1K – 4700
2025
Q4 		$39.1K Buy
1,816
+326
+22% +$6.33K ﹤0.01% 3187
2025
Q3 		$22.8K Buy
+1,490
New +$19.4K ﹤0.01% 3301
2023
Q1 		– Sell
-3,794
Closed -$26K – 2115
2022
Q4 		$26K Buy
3,794
+3,294
+659% +$23.1K ﹤0.01% 2690
2022
Q3 		$2K Sell
500
-424
-46% -$2.33K ﹤0.01% 3555
2022
Q2 		$2K Buy
+924
New +$3.79K ﹤0.01% 3750

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Rockefeller Capital Management's AVDL Position: Q1 2026 in Review

Rockefeller Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 1,816 shares — an estimated $39.1K sold.

Rockefeller Capital Management first reported a position in AVDL in Q2 2022 and held it in 5 quarters. The position peaked at $39.1K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Rockefeller Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 1,816 Avadel Pharmaceuticals shares in Q1 2026, an estimated $39.1K.
  • Rockefeller Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Rockefeller Capital Management's Avadel Pharmaceuticals position peaked at $39.1K in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.